期刊文献+

阿托伐他汀对颈动脉粥样硬化患者血浆同型半胱氨酸的影响 被引量:4

The effect of homocysteine of patients with carotid artery atherosclerosis
原文传递
导出
摘要 目的阿托伐他汀钙对老年颈动脉粥样硬化患者血浆同型半胱氨酸的(Hcy)作用。方法 96例老年颈动脉粥样硬化患者,随机分为3组,A组给予生活方式指导及服用拜阿司匹林,B组在A组基础上口服阿托伐他汀20 mg,C组在A组基础上口服阿托伐他汀40 mg,服药前及服药第4,6,8周分别测定斑块面积及血浆Hcy水平。结果 A组及B组斑块面积及Hcy水平较服药前无明显变化,C组斑块面积及Hcy水平于第6周降低,且第8周低于第6周。结论每日服用阿托伐他汀40 mg可降低颈动脉粥样硬化患者血浆Hcy水平,且此效应与其对颈动脉斑块面积的缩小作用时间保持一致。 Objective To observe the effects of atorvastatin calcium on plasma homocysteine of patients with carotid artery atherosclerosis.Methods Ninety-six patients with carotid artery atherosclerosis were divided into three groups.Patients of group A were given life style guidance and took 100 mg asprin per day as the base treatment.Patients of group B took extra 20 mg atorvastatin calcium orally on the basis of group A.In addition to the base treatment of group A,extra 40 mg atorvastatin calcium were taken orally by patients of group C.The area of carotid plaque and the level of homocysteine were detected before the treatment and on the 4th,6th,8th week after treatment respectively.Results No significant change was observed in group A and B before and after treatment in area of carotid plaque and the level of homocysteine,which decreased in group C from the 6th to 8th week,and more on the 8th week.Conclusion Taking 40 mg atorvastatin calcium everyday can help to decrease the homocysteine level of patients with carotid artery atherosclerosis,and this effect was parallel to the reduction of carotid plaque area.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第6期406-408,共3页 The Chinese Journal of Clinical Pharmacology
关键词 阿托伐他汀 同型半胱氨酸 颈动脉粥样硬化 atorvastatin homocysteine carotid artery atherosclerosis
  • 相关文献

参考文献8

  • 1Lee SJ,Kim KM,Namkoong S. Nitric oxide inhibition of homocysteine-induced human endothelial cell spop tosis by downregulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine[J].Journal of Biological Chemistry,2005.5781-5788.
  • 2Pitouìias GA,Tachtsi MD,Tsiaousis PZ. Hyperhomocysteinemia and hypercoaguìable state in carotid plaque evolution.Novel risk factors or coincidental risk predictors[J].International Angiology,2007.270-278.
  • 3Dayal S,Aming E,Bottiglieri T. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice[J].Stroke,2004.1957-1962.
  • 4Steed MM,Tyagi SC. Mechanism of cardiovascular remodeling in hyperhomocysteinemia[J].Antioaid Redox Signal,2011.1927-1943.
  • 5Gotlieb AI. Smooth muscle and endothelial cell function in the pathogenesis of atherosclerosis[J].Canadian Medical Association Journal,1982.903-908.
  • 6Hajjar KA,Mauri L,Jacovina AT. Tissue plasminogen activator binding to the annexin Ⅱ tail domain.Direct modulation by homocysteine[J].Journal of Biological Chemistry,1998.9987-9993.
  • 7Giral P,Bruckert E,Jacob N. Homocysteine and lipid lowering agents.A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia[J].Atheroclerosis,2001.421-427.
  • 8朱建华,邱立红,张必祺,孙坚.不同剂量辛伐他汀治疗对急性冠状动脉综合征患者几种炎症因子的影响[J].中华心血管病杂志,2004,32(11):972-976. 被引量:34

二级参考文献14

  • 1Russell R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340: 115-126.
  • 2Mueck AO, Seeger H. Statins and direct vascular actions. Panminerva Med, 2003, 45: 1-6.
  • 3Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on P
  • 4Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol, 2000,36: 95
  • 5Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin, 2003, 19: 540-556.
  • 6Hashimoto M, Akita H. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation, 2002, 105: E30-E31.
  • 7Ridker PM, Rifai N, Pfeffer MA, et al. Long term effects of pravastatin on plasma concentrations of C-reactive protein. The Cholesterol and Recurrent Events. (CARE) investigators. Circulation, 2000, 100: 230-235.
  • 8Kinlay S, Rifai N, Libby P, et al. Effect of atorvastatin on Creactive protein in patients with acute coronary syndrome: a substudy of the MIRACL trial. J Am Coll Cardiol, 2002, 39(Suppl A): 304A.
  • 9Ansell BJ, Watson KE, Weiss Re, et al. hs-CRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis, 2003, 5: 2-7.
  • 10Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation, 2002, 106: 1447-1452.

共引文献33

同被引文献62

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部